Key Highlights

  • Sight Sciences shares are down about 7% in pre-market trading despite positive company news.
  • Aetna's updated Glaucoma Surgery Policy now recognizes the OMNI and SION systems as medically necessary.
  • Q2 2026 total revenue reached $23.4 million, up 20% year over year, beating estimates.
  • Full-year 2026 revenue guidance was raised to $88 million to $89 million.
  • The company ended the quarter with $79.8 million in cash and no debt.

Shares Fall Despite Coverage Win and Earnings Beat

Sight Sciences is trading lower in pre-market action even after the company delivered positive news on both the payer coverage and earnings fronts. Shares fell as much as 7.35% to $5.14 in pre-market trading, extending a 1.60% decline from the prior regular session, despite what appears on the surface to be a favorable set of updates.

Aetna's updated Glaucoma Surgery Policy for commercial plans now recognizes the OMNI Surgical System and SION Surgical Instrument as medically necessary for the treatment of mild to moderate open angle glaucoma when specified clinical criteria are met. The coverage policy is retroactive to July 14, 2026, and Aetna is one of the largest health insurers in the United States with approximately 25 million total commercial covered lives.

Q2 Results Topped Estimates

On the earnings side, Sight Sciences reported total revenue of $23.4 million for the second quarter, up 20% year over year, marking the strongest quarterly revenue growth in three years, driven by growth in both interventional glaucoma and interventional dry eye segments. Interventional dry eye revenue hit a record $2.7 million, more than doubling sequentially from the first quarter.

The company raised full-year 2026 total revenue guidance to a range of $88 million to $89 million, up from a prior range of $83 million to $89 million, and also lifted adjusted operating expense guidance to a range of $93 million to $96 million. Cash used in operating activities was $5.4 million, and the company ended the quarter with $79.8 million in cash and no debt, while believing it can achieve cash flow breakeven without raising additional equity capital.

About Sight Sciences

Sight Sciences is an eyecare technology company headquartered in Menlo Park, California, focused on developing and commercializing interventional technologies to treat prevalent eye diseases. The company's OMNI Surgical System and SION Surgical Instrument are implant-free, minimally invasive tools used to reduce intraocular pressure in patients with open-angle glaucoma, while its TearCare System addresses evaporative dry eye disease.

What May Be Weighing on Shares

Despite the positive headlines, the stock's decline suggests investors may be focused on other factors, such as the pace of full-year guidance increases relative to expectations, or broader caution around medical device valuations following recent sector volatility. The company noted one-time items including a $5.4 million Alcon litigation settlement fee and $1.6 million in tariff refunds during the quarter, which could be contributing to a more complex read on underlying profitability trends.

Conclusion

Sight Sciences delivered a quarter with genuine positive developments, including expanded Aetna coverage and revenue growth that beat expectations, yet shares are trading lower as investors weigh other factors in the report. The company's expanding payer coverage and improving cash position remain notable long-term positives for the business.

Why is Sight Sciences stock down today despite positive news?

Despite a Q2 revenue beat and new Aetna coverage for its glaucoma devices, shares are trading lower, suggesting investors are focused on other elements of the report such as guidance pacing or one-time items.

What did Aetna's coverage decision mean for Sight Sciences?

Aetna now recognizes the OMNI Surgical System and SION Surgical Instrument as medically necessary for mild to moderate open-angle glaucoma, expanding payer access across roughly 25 million covered lives.

What was Sight Sciences' Q2 2026 revenue?

The company reported total revenue of $23.4 million, up 20% year over year.

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.